Key facts
- Notable investors include Hefei Industry Investment Group, Winreal Investment, GSR United Capital, Bangming Capital, Litian Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for OneTar Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for OneTar Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OneTar Biomedicine
Provider of organoid research platforms intended for new drug development in oncology research. The company's offerings include organoid culture systems for lung, gastrointestinal, liver, gallbladder, pancreatic, and breast cancers, along with translational research models, thereby improving disease modelling accuracy, drug screening efficiency and clinical relevance for research institutions and pharmaceutical companies.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- onetarjz.com/
- Ownership
- Privately Held (backing)
OneTar Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OneTar Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OneTar Biomedicine in its N-PORT filings yet. We sweep new filings monthly.